



MEMORANDUM #29

TO: UNCHCS Attending Physicians, Faculty Practice Physicians, Housestaff, Clinical Nurse Coordinators, Department Heads and Supervisors

FROM: *KW* Karen Weck, MD; Director, Molecular Genetics Laboratory
MCU Herbert C. Whinna MD, PhD; Medical Director, McLendon Clinical Laboratories

SUBJECT: **New Test – Breast Cancer Prognostic Gene Signature Assay (Prosigna) at UNCH**

DATE: August 29, 2019

Effective September 09, 2019 the Molecular Genetics Laboratory of UNC McLendon Clinical Laboratories (MCL) will offer Breast Cancer Prognostic Gene Signature Assay (Prosigna). Samples for this testing have previously been sent to LabCorp laboratories.

Clinical Significance

Prosigna® is indicated for testing in postmenopausal women with hormone receptor-positive, node-negative (Stage I or II), or node-positive (Stage II) breast cancer to be treated with adjuvant endocrine therapy for assessment of risk of distant recurrence of disease.

Specimen Requirements

Formalin Fixed Paraffin-Embedded (FFPE) breast tissue.

Turnaround time

The turn-around time of testing is two weeks

Test Order (EAP) number in EPIC

LAB8988

If you have any questions related to this change, please email Karen Weck (Karen.Weck@unchealth.unc.edu) or call the Molecular Genetics Laboratory at 984-974-1825.

Website <https://www.uncmedicalcenter.org/mclendon-clinical-laboratories/>